INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA

被引：0
|
作者：
Porter, J. [1 ]
Cappellini, M. D. [2 ]
Origa, R. [3 ]
Forni, G. L. [4 ]
Laadem, A. [5 ]
Galacteros, F. [6 ]
Voskaridou, E. [7 ]
Miteva, D. [5 ]
Sung, V. [5 ]
Chopra, R. [5 ]
Arlet, J. B. [8 ]
Ribeil, J. A. [8 ]
Klesczewski, K. [5 ]
Attie, K. [9 ]
Garbowski, M. [1 ]
Graziadei, G. [2 ]
Balocco, M. [4 ]
Hermine, O. [8 ]
机构：
[1] UCL, London, England
[2] Univ Milan, Ca Granda Fdn IRCCS, Milan, Italy
[3] Univ Cagliari, Osped Reg Microcitemie, Cagliari, Italy
[4] Ente Osped Osped Galliera, Genoa, Italy
[5] Celgene Corp, Summit, NJ USA
[6] Grp Hosp Henri Mondor, Creteil, France
[7] Laikon Gen Hosp, Athens, Greece
[8] Hop Necker Enfants Malad, Inst Imagine, Paris, France
[9] Acceleron Pharma, Cambridge, MA 02139 USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S662
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
    Paller, Amy
    Becker, Emily
    de Lucas, Raul
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Barcellona, Claire
    Maes, Peter
    Fiorillo, Loretta
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB120 - AB120
  • [32] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study
    Paller, A.
    Becker, E.
    de Lucas, R.
    Paris, M.
    Zhang, W.
    Zhang, Z.
    Barcellona, C.
    Maes, P.
    Fiorillo, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 174 - 175
  • [33] Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma
    Duvic, Madeleine
    Kim, Youn H.
    Zinzani, Pier Luigi
    Horwitz, Steven M.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3552 - 3556
  • [34] Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
    Danese, S.
    Klopocka, M.
    Scherl, E. J.
    Romatowski, J.
    Allegretti, J. R.
    Peeva, E.
    Vincent, M. S.
    Schoenbeck, U.
    Xi, L.
    Ye, Z.
    Hassan-Zahraee, M.
    Rath, N.
    Li, G.
    Neelakantan, S.
    Banfield, C.
    Lepsy, C.
    Chandra, D.
    Hung, K. E.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S109 - S109
  • [35] SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY
    Danese, Silvio
    Klopocka, Maria
    Scherl, Ellen J.
    Romatowski, Jacek A.
    Allegretti, Jessica R.
    Peeva, Elena
    Vincent, Michael S.
    Schoenbeck, Uwe
    Xi, Li
    Ye, Zhan
    Hassan-Zahraee, Mina
    Rath, Natalie
    Li, Gang
    Neelakantan, Srividya
    Banfield, Christopher
    Lepsy, Christopher
    Chandra, Deepa
    Hung, Kenneth E.
    GASTROENTEROLOGY, 2020, 158 (06) : S206 - S207
  • [36] An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
    Durrant, Simon T.
    Nagler, Arnon
    Vannucchi, Alessandro M.
    Lavie, David
    Chuah, Charles
    Passamonti, Francesco
    Gisslinger, Heinz
    le Coutre, Philipp
    Gopalakrishna, Prashanth
    Mahuzier, Bruyere
    Mo, Shuyuan
    Martinez-Lopez, Joaquin
    BLOOD, 2015, 126 (23)
  • [37] Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
    Powles, Thomas
    O'Donnell, Peter H.
    Massard, Christophe
    Arkenau, Hendrik-Tobias
    Friedlander, TerenceW.
    Hoimes, Christopher J.
    Lee, Jae Lyun
    Ong, Michael
    Sridhar, Srikala S.
    Vogelzang, Nicholas J.
    Fishman, Mayer N.
    Zhang, Jingsong
    Srinivas, Sandy
    Parikh, Jigar
    Antal, Joyce
    Jin, Xiaoping
    Gupta, Ashok K.
    Ben, Yong
    Hahn, Noah M.
    JAMA ONCOLOGY, 2017, 3 (09)
  • [38] Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis
    Khouri, Jack
    Anwer, Faiz
    Samaras, Christy J.
    Garcia, Alex V. Mejia
    Koc, Omer N.
    Faiman, Beth M.
    Hamilton, Kimberly
    Mathur, Saveta
    Scott, Cynthia
    Stefunek, Kathleen
    Sgobbo, Josephine
    Fada, Sherry
    Lewis, Brittany
    Shepherd, Kelly
    Ahmad, Naqib
    Knebusch, Madeleine
    Sobolov, Susan B.
    Jobes, Janet
    Daniel, Eileen
    Spector, Michael
    Valent, Jason
    BLOOD, 2020, 136
  • [39] LUSPATERCEPT (ACE-536) INCREASES HEMOGLOBIN AND DECREASES TRANSFUSION BURDEN AND LIVER IRON CONCENTRATION IN ADULTS WITH BETA-THALASSEMIA: PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Piga, A.
    Perrotta, S.
    Borgna-Pignatti, C.
    Gamberini, M. R.
    Melpignano, A.
    Voskaridou, E.
    Caruso, V.
    Filosa, A.
    Aydinok, Y.
    Zhang, X.
    Wilson, D.
    Laadem, A.
    Sherman, M.
    Attie, K.
    HAEMATOLOGICA, 2015, 100 : 17 - 17
  • [40] Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study
    Piga, Antonio
    Perrotta, Silverio
    Gamberini, M. Rita
    Voskaridou, Ersi
    Melpignano, Angela
    Filosa, Aldo
    Pietrangelo, Antonello
    Caruso, Vincenzo
    Forni, Gian Luca
    Zhang, Xiaosha
    Bellevue, Ashley
    Wilson, Dawn
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    BLOOD, 2015, 126 (23)
12345